4 results match your criteria: "County Hospital Bregenz[Affiliation]"
Associations of Polymorphisms in the Peroxisome Proliferator-Activated Receptor Gamma Coactivator-1 Alpha Gene With Subsequent Coronary Heart Disease: An Individual-Level Meta-Analysis.
Front Physiol
June 2022
Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden.
Article Synopsis
- The study investigates the role of specific genetic variants (SNPs) in the PPARGC1A gene on the risk of subsequent coronary heart disease (CHD) events in patients already diagnosed with the condition.* -
- Using data from 23 studies with nearly 81,000 participants, the researchers analyzed associations between three SNPs and the occurrence of CHD death or myocardial infarction, employing a Cox proportional hazards model.* -
- The meta-analysis found no significant links between the genetic variants and the risk of subsequent CHD events or cardiovascular diseases, except for some inverse associations observed in specific participant subgroups.*
PCSK9 inhibition in patients with heart failure: neutral or harmful intervention?
Eur Heart J
April 2022
Department of Internal Medicine, County Hospital Bregenz, Carl-Pedenz-Strasse 2, A-6900 Bregenz, Austria.
Type 2 diabetes and the risk of cardiovascular events in peripheral artery disease versus coronary artery disease.
BMJ Open Diabetes Res Care
November 2021
VIVIT, Vorarlberg Institute of Vascular Investigation and Treatment, Feldkirch, Vorarlberg, Austria
Introduction: The prevalence of type 2 diabetes mellitus (T2DM) is higher in peripheral artery disease (PAD) than in coronary artery disease (CAD) patients, and PAD overall confers higher cardiovascular risk than CAD. How cardiovascular risk compares between PAD and CAD patients when analyses are stratified by the presence of type 2 diabetes is unclear and is addressed in the present study.
Research Design And Methods: We prospectively recorded major cardiovascular events (MACE; ie, cardiovascular death, myocardial infarction or stroke) over 10.
Subgroup analyses in randomized clinical trials: value and limitations. Review #3 on important aspects of randomized clinical trials in cardiovascular pharmacotherapy.
Eur Heart J Cardiovasc Pharmacother
May 2022
Department of Cardiology, Oslo University Hospital, Ullevål, Oslo, Norway.